Garipalli Vivek

Director Garipalli Vivek purchased 446,980 shares for $998,996.60 across two transactions at $2.24 and $2.17, raising holdings to 1.86M shares (+31.7%).

Garipalli Vivek, a director at Clover Health, executed 2 separate purchases totaling 446,980 shares for $998,996.60 at a blended average price of $2.23 on August 7–8, 2025, increasing his holdings by 31.7% to 1,856,247 shares. His timing pattern at CLOV is noteworthy: his prior 2 buys at this ticker (June 2024 and August 2024) both delivered strong 90-day returns (+162.3% and +95.2%), suggesting a track record of favorable entry points. His cross-ticker track record shows 2 prior buys with a 100% 90-day win rate and an average 90-day return of +128.7%. However, the company backdrop is challenging: annual revenue declined 32.6% year-over-year, the firm posted a net loss of $10,578,000.00 over its most recent full fiscal year, and the stock has fallen 54.8% from its 52-week high and is down 31.2% over the past 30 days. The scale of this purchase—nearly $1M deployed and a 31.7% increase in personal holdings—against deteriorating fundamentals and recent sharp price declines presents a material insider accumulation that investors should monitor closely for signals about the director's conviction or potential upcoming catalysts.

Director Garipalli Vivek buys 531.7K shares of CLOV at $1.88; holdings rise 60.6% to 1.41M shares

Director Garipalli Vivek purchased 531,700 shares of Clover Health at $1.88 on 2024-08-09, increasing his holdings by 60.6% from 877,567 shares to 1,409,267 shares. The stock has appreciated 32.4% in the 30 days following the transaction and currently trades at $2.00, near its 52-week high. However, the company's fundamentals present a mixed picture: while it generated $356,260,000 in revenue last quarter with $7,408,000 in net income, annual revenue declined 41.5% year-over-year and the firm was unprofitable on a full-year basis. Across his open-market history, this director's prior buy showed a +50.9% 30-day return, but his historical timing pattern at the 90-day mark provides limited predictive power, and this transaction's longer-term outcome remains to be determined.

Director Garipalli Vivek buys 877.6K CLOV shares at $1.14 for $1.0M; stock now at $1.03, down -34.0% from 52-week high.

Director Garipalli Vivek initiated a new position in Clover Health with a $1.0M purchase of 877,567 shares at $1.14 on 2024-06-17, establishing 877.6K shares post-transaction with zero prior holdings. The purchase occurs in a company facing material headwinds: annual revenue declined -41.5% year-over-year, the company posted a net loss of $-19.2M in its latest quarter, and full-year net income was negative. The stock currently trades at $1.03, representing a -34.0% decline from the 52-week high of $1.56, suggesting the director's entry price of $1.14 was substantially above current valuation. This first-time director purchase into a structurally unprofitable, declining-revenue business warrants examination of whether market conditions or company fundamentals have deteriorated since the transaction date.